Merck to buy Schering-Plough in $41 billion deal Reported by David Jolly Publ With the purchase, Merck is expanding its franchise in cardiovascular, respiratory and oncology drugs and shoring up its research pipeline, in particular with a Schering-Plough product called TRA, a promising drug designed to prevent blood clotting. In addition, Merck will benefit from the [...]
The information in this post was gathered from an article published by Deb Bortifz in eCliniqua, Innovative Management in Clinical Trials. eCliniqua offers PodCasts, WebCasts, White Papers and much more. Their ‘data-rich’ site is one of my primary research resources for an objective review of clinical trial process and results. March 2, 2009 | A [...]
Goal Is to Provide Signs of Possibility Of Adverse Effect By JARED A. FAVOLE Wall Street Journal WASHINGTON The Food and Drug Administration on Friday unveiled a report listing 20 drugs that the agency is investigating for potential side effects, as part of a new policy to warn patients and health-care professionals as early [...]
Goal Is to Provide Signs of Possibility Of Adverse Effects By JARED A. FAVOLE WSJ.com, September 5, 2008 8:07 p.m. WASHINGTON — The Food and Drug Administration on Friday unveiled a report listing 20 drugs that the agency is investigating for potential side effects, as part of a new policy to warn patients and health-care [...]
© 2002- An Inconvenient Woman. Site design and construction by Pleiades Publishing Services, Co.
Powered by Wordpress and based on the template design MyJournal Hypereal by 
BlogoSquare
